

Terapevticheskii Arkhiv 2018 vol.90 N2, pages 35-42

European Registry on the management of *Helicobacter pylori* infection (Hp-EuReg): N analysis of 2360 patients receiving first-line therapy in Russia

Nyssen O., McNicholl A., Gisbert J.

Kazan Federal University, 420008, Kremlevskaya 18, Kazan, Russia

Abstract

© 2018 Media Sphaera Publishing Group. All rights reserved. European Registry on the management of *Helicobacter pylori* infection («Hp-EuReg») - a multicenter prospective observational study initiated by the European *Helicobacter* and Microbiota Study Group, conducted in 27 European countries in order to evaluate the real clinical practice of diagnosis and treatment of *H. pylori* and its comparison with international recommendations. Materials and methods. The analysis of 2360 patients entered in the register by the Russian centres of «Hp-EuReg» in 2013-2017, who were underwent 1st line eradication therapy. Results. The most common methods of primary diagnosis of *H. pylori* are histological (37.7%), rapid urease test (29.2%) and serology (29.7%). The duration of eradication therapy in 9.4% of cases was 7 days, in 65.3% - 10 days, and in 25.3% - 14 days. To control the effectiveness of treatment, *H. pylori* antigen in feces (31.3%), urea breath test (23.4%) and histological method (23.3%) were used. In 3.6% cases was used serology by mistake. In 17.3% of patients control was not carried out. The effectiveness of triple therapy with a PPI, amoxicillin, clarithromycin (per protocol) was 67.6%, with 7-day course, 81.1% at 10-day and 86.7% at 14-day course. Eradication rate of triple therapy with addition of bismuth (per protocol) reached 90,6% in the group receiving 10-day scheme and 93.6% in the group receiving the 14-day treatment. Conclusion. Significant deviations of clinical practice from expert recommendations, most pronounced at the stage of monitoring the effectiveness of therapy, were noted. The suboptimal efficacy of triple therapy is shown.

<http://dx.doi.org/10.26442/terarkh201890235-42>

Keywords

Eradication therapy., *Helicobacter pylori*, Hp-EuReg, Register

References

- [1] Baryshnikova NV, Tkachenko EI, Uspenskii YuP. Modern aspects of the problem of *Helicobacter pylori*-associated diseases. In: Lazebnik LB, Shcherbakov PL, editors. *Gastroenterologiya. Bolezni vzroslykh* [Gastroenterology. Disease adults]. Moscow: MK, 2011. P. 103 (In Russ.)
- [2] Lazebnik LB, Tkachenko EI, Abdulganieva DI, Abdulkhakov RA, Abdulkhakov SR, Avalueva EB, Ardatskaya MD, Akhmedov VA, Bordin DS, Burkov SG, Butov MA, et al. VI national guidelines for the diagnosis and treatment of acid-related and *Helicobacter pylori*-associated diseases (VI Moscow agreement). *Ekspertimnaya i Klinicheskaya Gastroenterologiya*. 2017;02(138):3-21 (In Russ.)

- [3] Malfertheiner P, Megraud F, O'Morain CA, Gisbert JP, Kuipers EJ, Axon AT, Bazzoli F, Gasbarrini A, Atherton J, Graham DY, Hunt R, Moayyedi P, Rokkas T, Rugge M, Selgrad M, Suerbaum S, Sugano K, El-Omar EM; European Helicobacter and Microbiota Study Group and Consensus panel. Management of Helicobacter pylori infection—the Maastricht V/Florence Consensus Report. *Gut*. 2017;66(1):6-30. doi: 10.1136/gutjnl-2016-312288
- [4] Lazebnik LB, Bordin DS. Diagnosis and treatment of diseases associated with Helicobacter pylori infection in real clinical practice: Results of the observational program "PARAD". *Vestnik Prakticheskogo Vracha*. 2014; 3(3):31-42 (In Russ.)
- [5] Malfertheiner P, Megraud F, O'Morain CA, et al. Management of Helicobacter pylori infection Maastricht IV/ Florence Consensus Report. *Gut*. 2012;61:646-64. doi: 10.1136/gutjnl-2012-302084
- [6] Sugano K, Tack J, Kuipers EJ, Graham DY, El-Omar EM, Miura S, Haruma K, Asaka M, Uemura N, Malfertheiner P; faculty members of Kyoto Global Consensus Conference. Kyoto global consensus report on Helicobacter pylori gastritis. *Gut*. 2015;64(9):1353-67. doi: 10.1136/gutjnl-2015-309252
- [7] Lee YC, Chen TH, Chiu HM, et al. The benefit of mass eradication of Helicobacter pylori infection: A community-based study of gastric cancer prevention. *Gut*. 2013;62:676-82. doi: 10.1136/gutjnl-2012-302240
- [8] Bordin DS, Masharova AA, Khomeriki SG. Chronic gastritis: A modern approach to an old problem. *Eksperimental'naya i Klinicheskaya Gastroenterologiya*. 2012;(5):99-106 (In Russ.)
- [9] Megraud F, Coenen S, Versporten A, et al. Helicobacter pylori resistance to antibiotics in Europe and its relationship to antibiotic consumption. *Gut*. 2013;62:34-42. doi: 10.1136/gutjnl-2012-302254
- [10] Graham DY, Lee YC, Wu MS. Rational Helicobacter pylori therapy: Evidence-based medicine rather than medicine-based evidence. *Clin Gastroenterol Hepatol*. 2014;12:177-86. doi: 10.1016/j.cgh. 2013.05.028
- [11] Bordin DS, Yanova OB, Abdulkhakov RA, Tsukanov VV, Livzan MA, et al. European register of Helicobacter pylori (Protocol Hp-EuReg): First results of Russian centers. *Terapevticheskii Arkhiv*. 2016;(2):33-8 (In Russ.)
- [12] Harris PA, Taylor R, Thielke R, Payne J, Gonzalez N, Conde JG. Research electronic data capture (REDCap) - A metadata-driven methodology and workflow process for providing translational research informatics support. *J Biomed Inform*. 2009;42(2):377-81. doi: 10.1016/j.jbi.2008.08.010
- [13] Ferwana M, Abdulmajeed I, Alhajahmed A, et al. Accuracy of urea breath test in Helicobacter pylori infection: Meta-analysis. *World J Gastroenterol*. 2015;21:1305-14. doi: 10.3748/wjg.v21.i4.1305
- [14] Zhou X, Su J, Xu G, et al. Accuracy of stool antigen test for the diagnosis of Helicobacter pylori infection in children; a meta-analysis. *Clin Res Hepatol Gastroenterol*. 2014;38:629-38. doi: 10.1016/j.clinre. 2014.02.001
- [15] McNicholl AG, Linares PM, Nyssen OP, Calvet X, Gisbert JP. Metaanalysis: Esomeprazole or rabeprazole vs. first-generation pump inhibitors in the treatment of Helicobacter pylori infection. *Aliment Pharmacol Ther*. 2012;36(5):414-25. doi: 10.1111/j.1365-2036.2012.05211
- [16] Chey WD, Leontiadis GI, Howden CW, Moss SF. ACG Clinical Guideline: Treatment of Helicobacter pylori Infection. *Am J Gastroenterol*. 2017;112(2):212-39. doi: 10.1038/ajg.2016.563
- [17] Simanenkov VI, Zakharova NV, Zhebrun AB, Svarval' AV, Savilova IV, Ferman RS. Resistance of Helicobacter pylori to antimicrobial agents according to the results of bacteriological testing. *Lechashchii Vrach*. 2015;(4):91 (In Russ.)
- [18] Dekhnich NN, Kostyakova EA, Punin AA, Alimov AV, Ivanchik NV, Kozlov RS. Antibiotic resistance of H. pylori: Results of microbiologic regional investigation. *Rossiiskii Zhurnal Gastroenterologii, Gepatologii, Koloproktologii*. 2011;21(2):37-42 (In Russ.)
- [19] Lazebnik LB, Masharova AA, Bordin DS, Khomeriki SG. Influence of bismuth on gastritis healing and effectiveness of helicobacter pylori eradication. *Helicobacter*. 2010;15:343.
- [20] Maev IV, Samsonov AA, Korovina TI, Grechushnikov VB, Andreev NG. Bismuth tripotassium dicitrate increases the effectiveness of H. pylori first-line therapy. *Eksperimental'naya i Klinicheskaya Gastroenterologiya*. 2012;(8):12-16 (In Russ.)
- [21] Sun Q, Liang X, Zheng Q, et al. High efficacy of 14-day triple therapybased, bismuth-containing quadruple therapy for initial Helicobacter pylori eradication. *Helicobacter*. 2010;15(3):233-8. doi: 10.1111/j. 1523-5378.2010.00758.x
- [22] Zhang W, Chen Q, Liang X, Liu W, Xiao S, Graham DY, Lu H. Bismuth, lansoprazole, amoxicillin and metronidazole or clarithromycin as first-line Helicobacter pylori therapy. *Gut*. 2015;64:1715-20. doi:10.1136/gutjnl-2015-309900